Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma
- 31 May 2011
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 105 (2) , 397-400
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomasNeurology, 2010
- Malignant Progression of a Pleomorphic Xanthoastrocytoma in a ChildNeuropediatrics, 2010
- Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a referenceBMC Cancer, 2010
- Anaplastic Pleomorphic Xanthoastrocytoma With a Component of Anaplastic Astrocytoma Presenting as Skull Base Tumor Followed by Downward Extracranial Extension -Case Report-Neurologia medico-chirurgica, 2010
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Pleomorphic xanthoastrocytoma: what do we really know about it?1999
- Pleomorphic xanthoastrocytomaCancer, 1999
- Pleomorphic Xanthoastrocytoma: Case Report and Analysis of the Literature Concerning the Efficacy of Resection and the Significance of NecrosisNeurosurgery, 1996